Core Viewpoint - Knight Therapeutics Inc. has submitted a marketing authorization application for NIKTIMVO (axatilimab) in Brazil for treating chronic graft-versus-host disease (GVHD) after failure of at least two prior systemic therapies in patients aged 6 years and older [1] Company Developments - Knight Therapeutics expanded its agreement with Incyte for exclusive distribution rights of retifanlimab and axatilimab in Latin America, with Incyte responsible for development and supply, while Knight handles regulatory approvals and distribution [2] - NIKTIMVO received FDA approval in August 2024 for chronic GVHD treatment in patients weighing at least 40 kg after failure of two prior systemic therapies [3] - The CEO of Knight emphasized the importance of new treatment options for chronic GVHD patients, highlighting the company's commitment to improving patient access to effective therapies [4] Industry Context - Chronic GVHD is a significant complication following allogeneic stem cell transplantation, affecting 30%-70% of recipients globally, with approximately 1,400 to 1,800 allogeneic transplants reported annually in Brazil [5] - The cumulative incidence of chronic GVHD after two years is reported to be 29.5% based on recent analyses [5] - NIKTIMVO is a first-in-class CSF-1R-blocking antibody, with ongoing studies for its efficacy in combination therapies for chronic GVHD and other conditions [6][8]

Core Viewpoint - Knight Therapeutics Inc. has received Health Canada approval for WYNZORA, a topical cream for treating psoriasis vulgaris in adults and adolescents aged 12-17, which combines calcipotriol and betamethasone dipropionate to enhance treatment adherence and symptom control [1][3][4]. Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [12]. - The company acquired the Canadian rights to WYNZORA through its acquisition of Paladin Pharma Inc. in June 2025 [2]. Product Details - WYNZORA is a cream-based fixed-dose combination of calcipotriol (0.05 mg/g) and betamethasone dipropionate (0.5 mg/g) designed for the topical treatment of psoriasis vulgaris [1][5]. - The product utilizes MC2's PAD Technology for effective drug delivery, allowing for a convenient aqueous formulation [5]. Clinical Trials and Efficacy - The approval from Health Canada is based on two randomized, investigator-blind, vehicle-controlled trials that demonstrated WYNZORA's superior efficacy compared to a vehicle and non-inferiority to CAL/BDP gel/suspension [6][8]. - In trial MC2-01-C2, WYNZORA showed a 14.6% greater treatment success compared to CAL/BDP gel/suspension, while trial MC2-01-C7 showed a 7.9% difference [8]. Market Impact - The introduction of WYNZORA is expected to improve the quality of life for Canadian patients suffering from psoriasis vulgaris, addressing both adherence and symptom control challenges [3][4]. - Psoriasis affects approximately 1 million Canadians and 125 million people globally, with chronic plaque psoriasis being the most common type [10][11].

Core Insights - Profound Medical Corp. has regained exclusive distribution rights for the TULSA-PRO system in Canada from Knight Therapeutics Inc. for a one-time payment of CDN$90,000 (US$64,000) and a 5% royalty on Canadian net sales for 15 years [3][4][5] Company Overview - Profound Medical Corp. is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [6][8] - The TULSA Procedure™ is designed to ablate prostate tissue in men suffering from prostate cancer and benign prostatic hyperplasia (BPH) [2][7] Technology and Procedure - The TULSA Procedure utilizes real-time MRI guidance and robotically guided ultrasound to precisely ablate targeted prostate tissue without harming surrounding structures [4][7] - The TULSA-PRO system is the only AI-powered, MRI-guided robotic system for prostate treatment, allowing for unmatched precision in therapy [4][7] - The procedure is incision-free, radiation-free, and typically performed in a single session, with most patients reporting quick recovery [7][8] Market Potential - Currently, there is only one Canadian site offering the TULSA Procedure, but there are plans to expand this through additional sites using a concierge service model [4][5] - The company aims to leverage results from the Level I prostate cancer CAPTAIN trial to support applications for health insurance coverage in Canada, which could significantly increase the market opportunity for the TULSA Procedure [4][5] Strategic Initiatives - Profound is deploying its own direct sales team in North America while partnering with strategic distribution partners to enhance business potential globally [5]

Core Insights - Knight Therapeutics Inc. reported a challenging quarter with an earnings per share (EPS) of -$0.02, missing the estimated EPS of -$0.005 [2][6] - The company's actual revenue was approximately $88 million, falling short of the estimated $107 million, although it showed an increase from the previous year [3][6] - The gross margin decreased to 46% from 49% last year, primarily due to increased costs associated with the Paladin and Sumitomo deals [3][6] Financial Metrics - The price-to-sales ratio is 1.56, and the enterprise value to sales ratio is 1.63, indicating the stock is valued at about 1.56 times its sales [4] - The debt-to-equity ratio stands at 0.14, reflecting a low level of debt compared to equity, suggesting financial stability [4] - The current ratio of 2.47 indicates a strong ability to cover short-term liabilities with short-term assets, ensuring liquidity [5]

Core Insights - Knight Therapeutics Inc. achieved record-high quarterly revenues, adjusted EBITDA, and adjusted EBITDA per share since inception, with increased financial guidance for 2025 [1][7][44] Financial Results - Revenues for Q3-25 were $121,548, an increase of $29,285 or 32% compared to Q3-24, driven by incremental revenues from the Paladin and Sumitomo Transactions and growth in key promoted products [6][12] - Adjusted revenues were $122,628, reflecting a 34% increase year-over-year [6][64] - Gross margin was $55,810 or 46% of revenues, down from 49% in the same period last year, impacted by hyperinflation and step-up expenses [6][16] - Operating income was $646, a significant decrease from $3,203 in Q3-24, while net loss was $3,791 compared to net income of $85 in the prior year [6][20] - Adjusted EBITDA reached $20,987, a 56% increase from the previous year, with adjusted EBITDA per share at $0.21, up 62% [6][64] Product Developments - Knight launched several products including Jornay PM™ in Canada, Minjuvi in Argentina, and Pemazyre in Brazil and Mexico [7][34][37] - The company expanded its partnership with Incyte for exclusive distribution rights of retifanlimab and axatilimab in Latin America [31] - Regulatory setbacks were noted for Tavalisse in Brazil and Qelbree in Canada, with appeals and responses planned [38][39] Corporate Developments - The company initiated a Normal Course Issuer Bid (NCIB) to purchase up to 3,000,000 common shares over the next 12 months [6][41] - Knight doubled its revolving credit facility to US$100 million, enhancing financial flexibility for future transactions [7][42] Financial Outlook - For fiscal 2025, Knight increased its revenue guidance to between $430 million to $440 million, up from $410 million to $420 million, with adjusted EBITDA expected to be between 13.5% to 14.5% of revenues [44]

Core Viewpoint - Knight Therapeutics Inc. has successfully closed a syndication of its US$100 million secured revolving credit facility, enhancing its financial flexibility for growth and acquisitions [1][3][5]. Group 1: Credit Facility Details - The credit facility was increased from an initial US$50 million to US$100 million, with an additional accordion feature allowing for another US$100 million, subject to lender acceptance [2][3]. - The facility has an initial maturity date of June 17, 2028, with the option for annual extensions of one year [4]. - The credit can be drawn in either USD or CAD at rates based on SOFR or CORRA plus a margin of 1.25% to 2.75%, depending on the company's debt leverage [4]. Group 2: Strategic Implications - The credit facility is intended to support the company's growth strategy and may also be utilized for working capital and other corporate purposes [3][5]. - The partnership with a consortium of four banks, led by National Bank of Canada, strengthens the company's financial relationships and doubles its borrowing capacity [5]. Group 3: Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [7].

Core Insights - Knight Therapeutics Inc. has launched JORNAY PM™, an extended-release formulation of methylphenidate for treating ADHD in children aged 6-12 in Canada [1][3][4] Company Overview - Knight Therapeutics Inc. is a pan-American specialty pharmaceutical company focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [9][10] - The company has entered into an agreement with Ironshore Pharmaceuticals for exclusive distribution rights of JORNAY PM™ in Canada and Latin America [4] Product Details - JORNAY PM™ is the first evening-dosed methylphenidate product available in Canada, designed to provide therapeutic benefits from morning until evening [7][8] - The product utilizes a unique delayed-release and extended-release technology, allowing for a smooth onset of effect at waking [2][7] - Clinical trials demonstrated significant improvement in ADHD symptom control throughout the day, with common adverse events including insomnia and decreased appetite [8] Market Context - The Canadian ADHD market is valued at approximately $1.25 billion in 2024, with methylphenidates accounting for over $500 million and experiencing a compound annual growth rate (CAGR) of more than 14% over the past four years [5]

Core Viewpoint - Knight Therapeutics Inc. is set to release its third quarter 2025 financial results on November 6, 2025, prior to market opening, followed by a conference call and audio webcast for interested parties [1]. Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focusing on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America [3]. - The company's Latin American subsidiaries operate under the names United Medical, Biotoscana Farma, and Laboratorio LKM [3]. - Knight Therapeutics Inc.'s shares are traded on the TSX under the symbol GUD [3]. Event Details - The conference call is scheduled for November 6, 2025, at 8:30 a.m. ET, with a toll-free telephone number provided for participants [1]. - An audio webcast will be available for listening, and a replay will be accessible for 30 days following the event [2].

Core Viewpoint - Knight Therapeutics Inc. has launched MINJUVI® in Argentina, marking a significant step in expanding access to innovative therapies for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT) [1][5]. Company Summary - Knight Therapeutics Inc. is a pan-American specialty pharmaceutical company focused on acquiring and commercializing pharmaceutical products in Canada and Latin America [11]. - The company has entered into a supply and distribution agreement with Incyte for the exclusive rights to distribute tafasitamab (MINJUVI®) in Latin America [6]. - The launch in Argentina is the third country launch for MINJUVI® in Latin America, reflecting the company's commitment to improving treatment options for patients [5]. Product Summary - MINJUVI® (tafasitamab) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, designed to treat adult patients with relapsed or refractory DLBCL [7]. - The approval for MINJUVI® in Argentina is based on the L-MIND trial, which showed an objective response rate (ORR) of 60%, with a complete response rate (CR) of 43% and a disease control rate (DCR) of 74% [3]. - MINJUVI® is recognized as a preferred second-line treatment for DLBCL patients who are ineligible for transplantation according to the 2024 National Comprehensive Cancer Network (NCCN) Guidelines [3]. Industry Context - DLBCL is the most common subtype of non-Hodgkin lymphoma, characterized by an aggressive clinical profile, with many patients developing refractory disease or relapsing after initial treatment [2]. - There is a significant need for new treatment options for patients facing poor prognoses due to the limitations of existing therapies [2].

Core Insights - Knight Therapeutics Inc. has relaunched MYFEMBREE, a treatment for uterine fibroids and endometriosis, in Canada, enhancing its women's health portfolio [1][4]. Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [7]. Product Details - MYFEMBREE is a fixed-dose combination of relugolix, estradiol, and norethindrone acetate, approved by Health Canada in September 2023, and is the first oral prescription treatment for managing heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis in pre-menopausal women [3][4]. - The total sales for gonadotropin-releasing hormone receptor (GnRH) agonist and antagonist products for endometriosis and uterine fibroids in Canada are estimated at $45 million, with a five-year CAGR of 8% [3]. Market Context - Uterine fibroids affect 20-30% of women of reproductive age, with 70-80% detected by age 50, often leading to symptoms like heavy menstrual bleeding and pelvic pain [5]. - Endometriosis affects approximately 10% of reproductive-aged women globally, with significant diagnostic delays and limited treatment options available [6].